Armstrong, A. J., Clarke, N. W., Thiery-Vuillemin, A., Oya, M., Procopio, G., De Menezes, J. J., … Saad, F. (2022). Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Armstrong, Andrew J., Noel W. Clarke, Antoine Thiery-Vuillemin, Mototsugu Oya, Giuseppe Procopio, Juliana Janoski De Menezes, Gustavo Colagiovanni Girotto, et al. “Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Armstrong AJ, Clarke NW, Thiery-Vuillemin A, Oya M, Procopio G, De Menezes JJ, et al. Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Armstrong, Andrew J., et al. “Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Armstrong AJ, Clarke NW, Thiery-Vuillemin A, Oya M, Procopio G, De Menezes JJ, Girotto GC, Ghatalia P, Din FNO, Spiegelhalder P, Mincik I, Van Alphen RJ, Lumen N, Hosius C, Zhou D, Barker L, Dujka ME, Saad F. Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. JOURNAL OF CLINICAL ONCOLOGY. 2022.